RGMb promoted CRC via Erk1/2-BMP4-Smad1/5/8 pathways and induced oxaliplatin resistance by inhibited JNK and p38 MAPK activation (Shi et al., 2015, 2016). This evidence concerns the gene MAPK3 and colorectal carcinoma.